Business
Genprex Announces Formation of Mesothelioma Clinical Advisory Board
Clinical Advisory Board to Provide Strategy for Advancing Preclinical Oncology Program in Mesothelioma AUSTIN, Texas, Sept. 19, 2024 /PRNewswire/ -- Genprex,
About this update from Genprex, Inc.
[{"type":"text","content":"Clinical Advisory Board to Provide Strategy for Advancing Preclinical Oncology Program in Mesothelioma\nAUSTIN, Texas, Sept. 19, 2024 /PRNewswire/ -- Genprex, Inc. (\"Genprex\" or the \"Company\") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced the formation of a Mesothelioma Clinical Advisory Board to support the Company's preclinical mesothelioma oncology program. The Board is comprised of four world-renown researchers from major research institutions specializing in the treatment of mesothelioma.\n\n \n \n \n \n \n \n\n \n\"We continue to develop a robust research program around our Reqorsa® Gene Therapy to expand its potential benefit to new patient populations, and we are pleased to assemble a group of highly respected physicians to assist in advancing our preclinical program in mesothelioma,\" said Ryan Confer, President and Chief Executive Officer at Genprex. \"This group of world class researchers will not only provide advice and input to assist the Genprex team in moving forward our potentially promising program in mesothelioma, but the formation of this board underscores our continuous efforts to advance our research programs in some of the most difficult to treat cancers with patients who have limited treatment options or an unmet medical need.\"\nExpression of TUSC2 is downregulated in 84% of mesotheliomas. Genprex collaborators at New York University Langone Health will present additional positive preclinical data on TUSC2 for the treatment of mesothelioma next month at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics. TUSC2 is the tumor suppressor gene used in Reqorsa® Gene Therapy (Quaratusugene ozeplasmid). REQORSA consists of a TUSC2 gene expressing plasmid encapsulated in non-viral lipid-based nanoparticles in a lipoplex form (the Company's Oncoprex® Delivery System), which has a positive charge. REQORSA is injected intravenously and specifically targets cancer cells. REQORSA is designed to deliver the functioning TUSC2 gene to negatively charged cancer cells while minimizing uptake by normal tissue. Laboratory studies conducted at MD Anderson show that the uptake of TUSC2 in tumor cells in vitro after REQORSA treatment was 10 to 33 times the uptake in normal cells.\nAccording...